CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children

Inclusion Criteria: 1. Ages 24 months to 55 years old at the time of enrollment 2. Diagnosed with DRE: not achieved seizure freedom, with adequate trials of 2 antiseizure medications 29 3. Medical history of 4 + clinically recognizable seizures (any type with clusters counted as a single event) per month 4. Have a negative pregnancy test at screening for patients who have experienced menarche 5. Agree to abstain from driving and recreational cannabis use throughout the study Exclusion Criteria: 1. Diagnosis of psychogenic non-epileptic seizure 2. Recent (\<30 days) change in anticonvulsant therapies including anticonvulsant medications, or settings on vagal nerve stimulator 3. Ketogenic diet started within 6 months (participants stable on the ketogenic diet for more than 6 months are eligible to participate) 4. Vagal nerve stimulator implanted and activated within 12 months 5. Concomitant regular use of narcotics (except in emergencies and physician supervised) 6. Initiation or dosage change of oral or injected steroids within 3 months 7. Allergy or intolerance to compounds in trial preparations 8. DRE secondary to progressive neurological disease 9. Clinically significant cardiac, renal or hepatic disease (as assessed by site investigator); elevated liver enzymes (GGT and/or AST and/or ALT) or lipase \>3 times upper limit, adjusted for age 10. History of psychotic disorders 11. Uncontrolled (in the perspective of the qualified investigator) medical conditions including substance use disorders 12. History or concurrent cannabis use disorder 13. Unwilling or unable to use highly effective methods of contraception throughout the study period and three months post-trial, where applicable